Compare KROS & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KROS | TALK |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 656.0M |
| IPO Year | 2020 | N/A |
| Metric | KROS | TALK |
|---|---|---|
| Price | $16.57 | $3.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $23.00 | $4.88 |
| AVG Volume (30 Days) | 266.1K | ★ 1.3M |
| Earning Date | 03-03-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.57 | 0.03 |
| Revenue | ★ $246,718,000.00 | $214,593,000.00 |
| Revenue This Year | $6,924.79 | $23.86 |
| Revenue Next Year | N/A | $22.25 |
| P/E Ratio | ★ $10.53 | $149.22 |
| Revenue Growth | ★ 37798.31 | 18.37 |
| 52 Week Low | $9.12 | $2.22 |
| 52 Week High | $22.55 | $4.36 |
| Indicator | KROS | TALK |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 47.27 |
| Support Level | $16.31 | $3.68 |
| Resistance Level | $17.17 | $3.99 |
| Average True Range (ATR) | 0.63 | 0.19 |
| MACD | -0.13 | -0.04 |
| Stochastic Oscillator | 18.26 | 21.37 |
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.